Previously, Jiang et al. compared CB2 with RF and found that CB2 treatment is associated with a significantly lower recurrence rate of AT; however, this study was based on evidence from observational studies, and a high heterogeneity among the trials was detected10. This evidence concerns the gene CNR2 and ataxia telangiectasia.